Clinical trials of IFN-β and other MS therapies in the 1990’s may not reflect the current immune ecology in MS, where higher levels of serum vitamin D now may enhance responses to IFN-β therapy and vaccinations [7,72–75,77]. This evidence concerns the gene IFNB1 and myeloid sarcoma.